9.29

0.43% 0.04

After Hours: 9.24 -0.05 -0.54%

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $9.29, with a volume of 816.34K. It is up +0.43% in the last 24 hours and up +7.90% over the past month. Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Previous Close:

$9.25

Open:

$9.34

24h Volume:

816.34K

Relative Volume:

0.57

Market Cap:

$824.61M

Revenue:

$67.48M

Net Income/Loss:

$-278.67M

P/E Ratio:

-2.9238

EPS:

-3.1774

Net Cash Flow:

$-70.70M

1W Performance:

+5.21%

1M Performance:

+7.90%

6M Performance:

-6.54%

1Y Performance:

+38.24%

1-Day Range:

$9.035

$9.415

1-Week Range:

$8.53

$9.42

52-Week Range:

$5.45

$12.49

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(858) 500-8800

Address

4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA

Employee

260

Twitter

@kuraoncology

Next Earnings Date

2026-05-07

Latest SEC Filings

KURA's Discussions on Twitter

Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KURA Kura Oncology Inc	9.29	821.06M	67.48M	-278.67M	-70.70M	-3.1774
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-14-24	Downgrade	Stifel	Buy → Hold
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

07:43 AM

Kura Oncology schedules May 12 webcast for Q1 2026 results - Stock Titan

07:43 AM

07:30 AM

Kura Oncology to Report First Quarter 2026 Financial Results - Yahoo Finance

07:30 AM

May 04, 2026

How The Kura Oncology (KURA) Story Is Evolving After Komzifti Launch And Q4 Reassessment - Yahoo Finance

May 04, 2026

Five new Kura hires get stock options for 133,750 shares - Stock Titan

May 04, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

May 04, 2026

May 01, 2026

KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill

May 01, 2026

Apr 30, 2026

Vanguard reports 5.01% stake in Kura Oncology (NASDAQ: KURA) - Stock Titan

Apr 30, 2026

Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance

Apr 30, 2026

Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA - MarketBeat

Apr 29, 2026

Apr 27, 2026

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - marketscreener.com

Apr 27, 2026

Apr 26, 2026

Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML - BioPharma APAC

Apr 26, 2026

Kura rises after early-stage trial data for kidney cancer therapy - MSN

Apr 26, 2026

Apr 22, 2026

Kura Oncology shares jump on encouraging kidney cancer trial results - MSN

Apr 22, 2026

KURA Financials: Income Statement, Balance Sheet & Cash Flow | Kura Oncology Inc - Stock Titan

Apr 22, 2026

Apr 21, 2026

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN

Apr 21, 2026